Angelini Ventures, the corporate venture arm of Italy’s family-owned Angelini Industries, has officially launched its first Asian office in Singapore’s CBD, according to a company statement. The office will serve as a regional hub for biotech and healthtech innovation, connecting startups with institutional partners and ecosystem leaders across Asia.
The Rome-based firm manages 300 million euros ($348 million) in evergreen capital, targeting early-stage companies in biotech, digital health, and life sciences. Since its founding in 2022, Angelini Ventures has invested 125 million euros across 22 startups globally.
Singapore-headquartered Nuevocor received $45 million in a Series B round co-led by Angelini Ventures in May 2025.
“Opening our first office in Asia isn’t just about a physical presence; it’s a gateway to learn from dynamic regional trends and accelerate growth,” said Sergio Marullo di Condojanni, CEO of Angelini Industries.
Paolo Di Giorgio, CEO of Angelini Ventures, added: “Asia is a hotspot for life sciences innovation. Governments are unlocking capital, boosting R&D, and strengthening talent pools. Singapore is the ideal base to tap into this ecosystem.”
The office will be led by Elia Stupka, who has over 20 years in healthcare and life sciences, spanning academic, clinical, and industry roles. He co-founded Singapore’s first genomics lab with Nobel Laureate Dr. Sydney Brenner.
Angelini Ventures will partner with Enterprise Singapore to launch a programme to provide mentorship, business development support, and global market access for biomedical startups.
The firm will also collaborate with AI Singapore on AI-driven biomedical solutions, including joint pitch events.
